Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 12/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30346628 | 1.00 | TDO2 (0.41) | TDO2IRAK1DYRK1ACLK2CLK3 | |
| SCHEMBL25208447 | 0.91 | TDO2 (0.44) | TDO2IRAK1DYRK1ACLK2CLK3 | |
| SCHEMBL30348149 | 0.91 | TDO2 (0.44) | TDO2IRAK1DYRK1ACLK2CLK3 | |
| SCHEMBL30346583 | 0.89 | DYRK1A (0.43) | TDO2DYRK1ACLK2CLK3BRD4 | |
| SCHEMBL25194734 | 0.89 | DYRK1A (0.43) | TDO2DYRK1ACLK2CLK3BRD4 | |
| SCHEMBL25211350 | 0.87 | TDO2 (0.38) | TDO2DYRK1ACLK2CLK3BRD4 | |
| SCHEMBL30346621 | 0.87 | TDO2 (0.38) | TDO2DYRK1ACLK2CLK3BRD4 | |
| SCHEMBL25157746 | 0.85 | TDO2 (0.39) | TDO2DYRK1ACLK2CLK3BRD4 | |
| SCHEMBL30347239 | 0.85 | TDO2 (0.39) | TDO2DYRK1ACLK2CLK3BRD4 | |
| SCHEMBL25195220 | 0.84 | TDO2 (0.38) | TDO2DYRK1ACLK2CLK3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | claimed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | claimed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | TDO2 539/4885IRAK1 873/4885DYRK1A 1/4885 |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | TDO2 539/4885IRAK1 873/4885DYRK1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.